AML WITH MUTATED NPM1
Clinical trials for AML WITH MUTATED NPM1 explained in plain language.
Never miss a new study
Get alerted when new AML WITH MUTATED NPM1 trials appear
Sign up with your email to follow new studies for AML WITH MUTATED NPM1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemia: experimental combo enters human testing
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or KMT…
Matched conditions: AML WITH MUTATED NPM1
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 17, 2026 08:12 UTC
-
New drug combo shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…
Matched conditions: AML WITH MUTATED NPM1
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New cell therapy targets tough blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new cell therapy called BSB-2002 in adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to at least two prior treatments. The main goal is to check the safety of BSB-2002 and see if it can help prevent the …
Matched conditions: AML WITH MUTATED NPM1
Phase: PHASE1 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated May 13, 2026 16:03 UTC